SCYNEXIS

+$0.05 (+2.69%) As of 1:41 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SCYNEXIS and other ETFs, options, and stocks.

About SCYX

SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.

CEO
Marco Taglietti
Employees
56
Headquarters
Jersey City, New Jersey
Founded
1999

SCYX Key Statistics

Market cap
62.23M
Price-Earnings ratio
—
Dividend yield
—
Average volume
72.32K
High today
$1.91
Low today
$1.86
Open price
$1.88
Volume
1.29K
52 Week high
$8.10
52 Week low
$1.70

SCYX Earnings

-$3.78
-$2.52
-$1.26
$0.00
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 15, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure